CTMX FY 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+376.1% YoY

Gross Profit

$72M100.0% margin

Operating Income

-$46M-64.6% margin

Net Income

-$43M-60.2% margin

EPS (Diluted)

$-1.16

Cash Flow

Operating Cash Flow

$170M

Free Cash Flow

$169M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$398M

Total Liabilities

$328M

Stockholders' Equity

$70M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$15M	+376.1%
Gross Profit	$72M	$15M	+376.1%
Operating Income	-$46M	-$60M	+22.4%
Net Income	-$43M	-$59M	+26.8%